Clinical Trials – Talk Bio

MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene

20 hours ago talkbio0Tagged Adagene, Antibodies, Bispecific, Arc Bio, CD3 T cell, Clinical Trials, engagers, licensing agreement, lorigerlimab, MacroGenics, mCRPC, SAFEbody technology

MacroGenics; lorigerlimab; bispecific antibody; mCRPC; clinical trial halt; Third Arc Bio; Adagene; SAFEbody technology; CD3 T cell engagers; licensing agreement; biotech deals

Chinese Biotechs Shed Fast-Follower Reputations as Innovation Surges in 2025

2 days ago talkbio0Tagged Biopharma, China, Chinese Language, Clinical Trials, drug candidates, global drug pipeline, innovation, leader, R&D, regulatory reforms

Chinese biotech innovation; fast-follower to leader; biopharma R&D; global drug pipeline; regulatory reforms; clinical trials; Made in China 2025; novel drug candidates

Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study

4 days ago talkbio0Tagged Biosciences, Clinical Trials, depression drug, Depressive disorder, Drug licensing, NBI-1070770, Neurocrine, pharmaceutical setbacks, Phase 2 Failure, psychiatry pipeline, Takeda

Neurocrine Biosciences; Takeda; NBI-1070770; Phase 2 failure; major depressive disorder; depression drug; psychiatry pipeline; clinical trial results; drug licensing; pharmaceutical setbacks

Cogent Biosciences Soars on Positive Phase 3 PEAK Results in Gastrointestinal Stromal Tumors (GIST)

4 days ago talkbio0Tagged bezuclastinib, Clinical Trials, Cogent Biosciences, Frequency of Responses, Gastrointestinal Stromal Tumors, NDA, Phase 3, Progression-Free Survival, Standard (qualifier), Stock Surge, Submission, sunitinib

Cogent Biosciences; bezuclastinib; sunitinib; GIST; Phase 3; progression-free survival; objective response rate; NDA submission; clinical trial; stock surge; standard of care

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

4 days ago talkbio0Tagged AnaptysBio, CAR-T therapy, Clinical Failure, Clinical Trials, Discontinuation (procedure), Lyell Immunopharma, News [Publication Type], Phase 2 trial, Rheumatoid Arthritis, Rosnilimab, Ulcerative Colitis

AnaptysBio; rosnilimab; ulcerative colitis; Phase 2 trial; clinical failure; trial discontinuation; Lyell Immunopharma; CAR-T therapy; licensing deal; biotech news; rheumatoid arthritis

Compugen Reports Third Quarter 2025 Results: Earnings Beat, Clinical Progress, and Cash Runway Extended

4 days ago talkbio0Tagged AstraZeneca, cash runway, Clinical Trials, clinical-stage immunotherapy, COM503, COM701, Compugen, earnings beat, Gilead, GS-0321, net loss, Revenue, rilvegostomig, third quarter 2025

Compugen; third quarter 2025; earnings beat; clinical-stage immunotherapy; revenue; net loss; cash runway; clinical trials; COM701; COM503 (GS-0321); rilvegostomig; AstraZeneca; Gilead

Spotlight On: What to Watch at AHA 2025 – Key Science and Trends

4 days ago talkbio0Tagged 2025, Autoimmune hemolytic anemia, Cardiology discipline, cardiometabolic, Cardiopulmonary Resuscitation, Clinical Trials, coronary trials, gene editing therapies, Guidelines, Hypertensive disease, Interventional procedure, lipid management, Medical Valves, polypill, Science

AHA 2025; late-breaking science; clinical trials; cardiology; gene-editing therapies; polypill; lipid management; valve and coronary trials; cardiometabolic intervention; hypertension; CPR guidelines

UbiVac Showcases First ‘Dark Matter’ Cancer Immunotherapy Clinical Data at SITC 2025 Annual Meeting

4 days ago talkbio0Tagged Allogeneic Autophagosome-enriched Vaccine DPV-001, alternatives, anti-PD-1, Clinical Trials, Combined Modality Therapy, Dark color, dark matter, Genome, immunopeptidome, Immunotherapy for cancer, Malignant Head and Neck Neoplasm, Neoantigen, SITC, T-Cell Receptor, UbiVac

UbiVac; DPV-001; cancer immunotherapy; dark matter; dark genome; alternatives neoantigens; T cell receptor (TCR); head and neck cancer; SITC 2025; clinical trial; combination therapy; anti-PD-1; immunopeptidome

Amgen’s Repatha Reduces First-Time Cardiovascular Events by 25% in Major Clinical Trial

4 days ago talkbio0Tagged amgen, Cardiovascular event, Cholesterol Drug, Clinical Trials, evolocumab, LDL Cholesterol Lipoproteins, Myocardial Infarction, PCSK9 inhibitor, Primary Prevention, Repatha, VESALIUS-CV

Amgen; Repatha; evolocumab; cholesterol drug; PCSK9 inhibitor; cardiovascular events; clinical trial; VESALIUS-CV; primary prevention; heart attack; LDL cholesterol

Vir Biotechnology’s Phase 2 Data for Hepatitis D Combo Regimen Highlights Market Potential

5 days ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, ECLIPSE program, elebsiran, HDV RNA, Hepatitis D Infection, Market, Phase 2, SOLSTICE, tobevibart, Undetectable, Vir Biotechnology

Vir Biotechnology; Phase 2; hepatitis D; combination therapy; tobevibart; elebsiran; SOLSTICE trial; undetectable HDV RNA; market potential; ECLIPSE program